CC
GMAB icon

Callan Capital’s Genmab GMAB Stock Holding History

Callan Capital’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$281K Buy
+14,361
New +$301K 0.02% 297

Other funds holding GMAB

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Callan Capital's GMAB Position: Q1 2025 in Review

Callan Capital opened a new position in Genmab (GMAB) in Q1 2025: 14,361 shares worth $281K. The stake represents 0.02% of the portfolio and ranks #297 among its holdings.

219 funds tracked by Wall St. Rank hold GMAB as of Q1 2025.

  • Callan Capital held 14,361 shares of Genmab worth $281K as of Q1 2025.
  • Genmab was a new Callan Capital position in Q1 2025.
  • Genmab made up 0.02% of Callan Capital's portfolio in Q1 2025, its #297 holding.
  • 219 funds tracked by Wall St. Rank held Genmab as of Q1 2025.

Based on Callan Capital's 13F filing for Q1 2025, filed 29 Apr 2025.